Cholesterol drug may shield ears from chemo damage
NCT ID NCT04915183
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether atorvastatin, a widely used cholesterol medication, can reduce hearing loss caused by cisplatin chemotherapy in people with head and neck cancer. About 224 adults will be randomly assigned to take atorvastatin or a placebo daily during and for three months after their cancer treatment. Hearing tests and blood samples will be collected before, during, and up to two years after treatment to see if the drug makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atorvastatin
What this could lead to
If it works, this could offer a simple, low-cost way to protect hearing during chemotherapy without affecting cancer treatment.
What could go wrong
This is a mid-stage trial with 224 people, so results are not yet proven. Atorvastatin may not prevent hearing loss, and there is a small risk of side effects like muscle pain or liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEARING LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Schar Cancer Center
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Maryland Medical Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wilmot Cancer Institute at the University of Rochester Medical Center in New Yor
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute at Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••